What is HC Wainwright's Forecast for enGene Q1 Earnings?

Key Points

• HC Wainwright has projected enGene Holdings Inc. to report a Q1 2026 earnings per share of ($0.64), with a current full-year earnings estimate of ($1.56) per share.
• The stock has a current Buy rating from HC Wainwright and a target price of $25.00, while Morgan Stanley has lowered its price objective from $19.00 to $18.00.
• enGene's shares opened at $5.71, reflecting a recent decline of 5.8% and an overall market cap of approximately $291.78 million.

enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of enGene in a research note issued to investors on Friday, September 12th. HC Wainwright analyst A. Maldonado expects that the company will earn ($0.64) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for enGene's current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for enGene's Q2 2026 earnings at ($0.59) EPS and Q3 2026 earnings at ($0.63) EPS.

enGene (NASDAQ:ENGN - Get Free Report) last announced its quarterly earnings results on Thursday, September 11th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06).

Separately, Morgan Stanley dropped their price target on enGene from $19.00 to $18.00 and set an "overweight" rating for the company in a research note on Friday, September 12th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $21.00.

enGene Price Performance

Shares of ENGN traded down $0.14 during trading hours on Monday, reaching $6.82. The stock had a trading volume of 61,767 shares, compared to its average volume of 361,657. enGene has a 12 month low of $2.65 and a 12 month high of $11.00. The stock has a market capitalization of $348.50 million, a PE ratio of -3.59 and a beta of -0.39. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.34 and a current ratio of 10.34. The company's 50-day moving average is $4.40 and its two-hundred day moving average is $4.15.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Cresset Asset Management LLC bought a new position in shares of enGene in the 2nd quarter worth about $36,000. Paloma Partners Management Co bought a new position in shares of enGene in the 2nd quarter worth about $38,000. Jane Street Group LLC bought a new position in shares of enGene in the 4th quarter worth about $93,000. Toronto Dominion Bank bought a new position in shares of enGene in the 4th quarter worth about $97,000. Finally, Cubist Systematic Strategies LLC raised its position in shares of enGene by 15.7% in the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock worth $102,000 after acquiring an additional 2,080 shares in the last quarter. 64.16% of the stock is owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.